Literature DB >> 22711356

Persistence of immunity to tick-borne encephalitis after vaccination and natural infection.

Tatjana Baldovin1, Rosanna Mel, Chiara Bertoncello, Graziella Carpenè, Fabio Soppelsa, Aurore Giliberti, Vincenzo Baldo.   

Abstract

Long-term persistence of immunity was assessed in 66 patients who had contracted tick-borne encephalitis (TBE) and in 126 subjects who had completed primary TBE immunization using a conventional three-dose schedule from 3 to 8 years earlier. Immunity was tested in the subjects stratified by age as follows: ≤40 years (N = 37); 41-60 years (N = 100); and over 60 years (N = 55). Antibody levels decreased significantly with increasing age in the vaccinated cohort by comparison with the individuals who had previously contracted TBE. Consistently higher geometric mean antibody levels were found in the patients infected naturally. When the vaccinated subjects were compared, subjects ≤40 years old had significantly higher antibody levels than either of the older groups. Analyzing immunity to TBE over time revealed a remarkable (50%) decline in seroprotection rates in the vaccinated group at 50 months of follow-up, while stable, high levels persisted in all subjects after natural TBE infection. In the vaccinees over 60 years old, the TBE antibody levels reached 60% at 60 months, and 20% at 70 months of follow-up; in contrast, in the 41-60-year-old group, the antibody levels remained high for 70 months, and then fell rapidly. For people aged <60 years old, booster doses are recommended every 5 years after the fourth dose of vaccine, which should be administered 3 years after primary immunization. In subjects aged 60 years or older, booster doses should be given every 3 years.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711356     DOI: 10.1002/jmv.23313

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

Review 1.  Neurological complications of tick borne encephalitis: the experience of 89 patients studied and literature review.

Authors:  Sandro Zambito Marsala; Michele Pistacchi; Manuela Gioulis; Rosanna Mel; Corrado Marchini; Ermenegildo Francavilla
Journal:  Neurol Sci       Date:  2013-10-30       Impact factor: 3.307

2.  Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.

Authors:  Ran Wang; Lyu Xie; Na Gao; Dongying Fan; Hui Chen; Peigang Wang; Hongning Zhou; Jing An
Journal:  Virol Sin       Date:  2019-03-25       Impact factor: 4.327

Review 3.  Vaccination against Tick-Borne Encephalitis (TBE) in Italy: Still a Long Way to Go.

Authors:  Donatella Panatto; Alexander Domnich; Daniela Amicizia; Paolo Reggio; Raffaella Iantomasi
Journal:  Microorganisms       Date:  2022-02-18

4.  Comparison of four serological tests for detecting antibodies to Japanese encephalitis virus after vaccination in children.

Authors:  Go Woon Cha; Jung Eun Cho; Young Ran Ju; Young-Jin Hong; Myung Guk Han; Won-Ja Lee; Eui Yul Choi; Young Eui Jeong
Journal:  Osong Public Health Res Perspect       Date:  2014-09-06

5.  Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection.

Authors:  Alexander J McAuley; Bevan Sawatsky; Thomas Ksiazek; Maricela Torres; Miša Korva; Stanka Lotrič-Furlan; Tatjana Avšič-Županc; Veronika von Messling; Michael R Holbrook; Alexander N Freiberg; David W C Beasley; Dennis A Bente
Journal:  NPJ Vaccines       Date:  2017-03-13       Impact factor: 7.344

6.  Analysis of Multiple Risk Factors for Seronegative Rate of Anti-Tick-Borne Encephalitis Virus Immunization in Human Serum.

Authors:  Marta Janik; Sylwia Płaczkowska; Mieczysław Woźniak; Iwona Bil-Lula
Journal:  Medicina (Kaunas)       Date:  2020-05-20       Impact factor: 2.430

7.  Factors determining immunological response to vaccination against tick-borne encephalitis virus in older individuals.

Authors:  Pontus Lindblom; Peter Wilhelmsson; Linda Fryland; Andreas Matussek; Mats Haglund; Johanna Sjöwall; Sirkka Vene; Dag Nyman; Pia Forsberg; Per-Eric Lindgren
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

8.  Prevalence of Neutralizing Antibodies to Japanese Encephalitis Virus among High-Risk Age Groups in South Korea, 2010.

Authors:  Eun Ju Lee; Go-Woon Cha; Young Ran Ju; Myung Guk Han; Won-Ja Lee; Young Eui Jeong
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

Review 9.  Primary vaccine failure to routine vaccines: Why and what to do?

Authors:  Ursula Wiedermann; Erika Garner-Spitzer; Angelika Wagner
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.